US2003181428A1PendingUtilityA1

Methods and compositions for inhibition of angiogenesis

60
Priority: Oct 16, 1997Filed: Oct 15, 2002Published: Sep 25, 2003
Est. expiryOct 16, 2017(expired)· nominal 20-yr term from priority
Inventors:Shawn J. GreenGlenn SwartzJamshed H. ShahJohn MadsenRobert D'Amato
A61K 31/445A61K 31/535A61K 31/4035A61K 31/19A61K 31/44A61K 31/40A61K 31/454
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A method of treating undesired angiogenesis comprising administering to a human or animal with undesired angiogenesis a composition comprising an effective amount of EM-138.  
     
     
         2 . The method of  claim 1  wherein the undesired angiogensis occurs in diabetic retinopathy.  
     
     
         3 . The method of  claim 1  wherein the undesired angiogensis occurs in retinopathy of prematurity.  
     
     
         4 . The method of  claim 1  wherein the undesired angiogensis occurs in corneal graft rejection.  
     
     
         5 . The method of  claim 1  wherein the undesired angiogensis occurs in neovascular glaucoma.  
     
     
         6 . The method of  claim 1  wherein the undesired angiogensis occurs in retrolental fibroplasia.  
     
     
         7 . The method of  claim 1  wherein the undesired angiogensis occurs in epidemic keratoconjunctivitis.  
     
     
         8 . The method of  claim 1  wherein the undesired angiogensis occurs due to Vitamin A deficiency.  
     
     
         9 . The method of  claim 1  wherein the undesired angiogensis occurs due to contact lens overwear.  
     
     
         10 . The method of  claim 1  wherein the undesired angiogensis occurs in atopic keratitis.  
     
     
         11 . The method of  claim 1  wherein the undesired angiogensis occurs in superior limbic keratitis.  
     
     
         12 . The method of  claim 1  wherein the undesired angiogensis occurs in pterygium keratitis sicca.  
     
     
         13 . The method of  claim 1  wherein the undesired angiogensis occurs in sjogren's syndrome.  
     
     
         14 . The method of  claim 1  wherein the undesired angiogensis occurs in acne rosacea.  
     
     
         15 . The method of  claim 1  wherein the undesired angiogensis occurs in phylectenulosis.  
     
     
         16 . The method of  claim 1  wherein the undesired angiogensis occurs in syphilis.  
     
     
         17 . The method of  claim 1  wherein the undesired angiogensis occurs in Mycobacteria infections other than leprosy.  
     
     
         18 . The method of  claim 1  wherein the undesired angiogensis occurs in lipid degeneration.  
     
     
         19 . The method of  claim 1  wherein the undesired angiogensis occurs in chemical burns.  
     
     
         20 . The method of  claim 1  wherein the undesired angiogensis occurs in bacterial ulcers.  
     
     
         21 . The method of  claim 1  wherein the undesired angiogensis occurs in fungal ulcers.  
     
     
         22 . The method of  claim 1  wherein the undesired angiogensis occurs in  Herpes simplex  infections.  
     
     
         23 . The method of  claim 1  wherein the undesired angiogensis occurs in  Herpes zoster  infections.  
     
     
         24 . The method of  claim 1  wherein the undesired angiogensis occurs in protozoan infections.  
     
     
         25 . The method of  claim 1  wherein the undesired angiogensis occurs in Kaposi's sarcoma.  
     
     
         26 . The method of  claim 1  wherein the undesired angiogensis occurs in Mooren's ulcer.  
     
     
         27 . The method of  claim 1  wherein the undesired angiogensis occurs in Terrien's marginal degeneration.  
     
     
         28 . The method of  claim 1  wherein the undesired angiogensis occurs in marginal keratolysis.  
     
     
         29 . The method of  claim 1  wherein the undesired angiogensis is caused by trauma.  
     
     
         30 . The method of  claim 1  wherein the undesired angiogensis occurs in rheumatoid arthritis.  
     
     
         31 . The method of  claim 1  wherein the undesired angiogensis occurs in systemic lupus.  
     
     
         32 . The method of  claim 1  wherein the undesired angiogensis occurs in polyarteritis.  
     
     
         33 . The method of  claim 1  wherein the undesired angiogensis occurs in Wegener's sarcoidosis.  
     
     
         34 . The method of  claim 1  wherein the undesired angiogensis occurs in scleritis.  
     
     
         35 . The method of  claim 1  wherein the undesired angiogensis occurs in Stevens-Johnson disease.  
     
     
         36 . The method of  claim 1  wherein the undesired angiogensis occurs in radial keratotomy.  
     
     
         37 . The method of  claim 1  wherein the undesired angiogensis occurs in macular degeneration.  
     
     
         38 . The method of  claim 1  wherein the undesired angiogensis occurs in sickle cell anemia.  
     
     
         39 . The method of  claim 1  wherein the undesired angiogensis occurs in sarcoid.  
     
     
         40 . The method of  claim 1  wherein the undesired angiogensis occurs in pseudoxanthoma elasticum.  
     
     
         41 . The method of  claim 1  wherein the undesired angiogensis occurs in Paget's disease.  
     
     
         42 . The method of  claim 1  wherein the undesired angiogensis occurs in vein occlusion.  
     
     
         43 . The method of  claim 1  wherein the undesired angiogensis occurs in artery occlusion.  
     
     
         44 . The method of  claim 1  wherein the undesired angiogensis occurs in carotid obstructive disease.  
     
     
         45 . The method of  claim 1  wherein the undesired angiogensis occurs in chronic uveitis.  
     
     
         46 . The method of  claim 1  wherein the undesired angiogensis occurs in chronic vitritis.  
     
     
         47 . The method of  claim 1  wherein the undesired angiogensis occurs in Lyme's disease.  
     
     
         48 . The method of  claim 1  wherein the undesired angiogensis occurs in Eales' disease.  
     
     
         49 . The method of  claim 1  wherein the undesired angiogensis occurs in Behcet's disease.  
     
     
         50 . The method of  claim 1  wherein the undesired angiogensis occurs in myopia.  
     
     
         51 . The method of  claim 1  wherein the undesired angiogensis occurs in optic pits.  
     
     
         52 . The method of  claim 1  wherein the undesired angiogensis occurs in Stargardt's disease.  
     
     
         53 . The method of  claim 1  wherein the undesired angiogensis occurs in pars planitis.  
     
     
         54 . The method of  claim 1  wherein the undesired angiogensis occurs in chronic retinal detachment.  
     
     
         55 . The method of  claim 1  wherein the undesired angiogensis occurs in hyperviscosity syndromes.  
     
     
         56 . The method of  claim 1  wherein the undesired angiogensis occurs in toxoplasmosis.  
     
     
         57 . The method of  claim 1  wherein the undesired angiogensis occurs in post-laser complications.  
     
     
         58 . The method of  claim 1  wherein the undesired angiogensis occurs due to abnormal proliferation of fibrovascular or fibrous tissue.  
     
     
         59 . The method of  claim 1  wherein the undesired angiogensis occurs in hemangiomas.  
     
     
         60 . The method of  claim 1  wherein the undesired angiogensis occurs in Osler-Weber-Rendu disease.  
     
     
         61 . The method of  claim 1  wherein the undesired angiogensis occurs in solid tumors.  
     
     
         62 . The method of  claim 1  wherein the undesired angiogensis occurs in blood borne tumors.  
     
     
         63 . The method of  claim 1  wherein the undesired angiogensis occurs in acquired immune deficiency syndrome.  
     
     
         64 . The method of  claim 1  wherein the undesired angiogensis occurs in ocular neovascular disease.  
     
     
         65 . The method of  claim 1  wherein the undesired angiogensis occurs in age-related macular degeneration.  
     
     
         66 . The method of  claim 1  wherein the undesired angiogensis occurs in osteoarthritis.  
     
     
         67 . The method of  claim 1  wherein the undesired angiogensis occurs in diseases caused by chronic inflammation.  
     
     
         68 . The method of  claim 1  wherein the undesired angiogensis occurs in Crohn's disease.  
     
     
         69 . The method of  claim 1  wherein the undesired angiogensis occurs in ulceritive colitis.  
     
     
         70 . The method of  claim 1  wherein the undesired angiogensis occurs in the tumors of rhabdomyosarcoma.  
     
     
         71 . The method of  claim 1  wherein the undesired angiogensis occurs in the tumors of retinoblastoma.  
     
     
         72 . The method of  claim 1  wherein the undesired angiogensis occurs in the tumors of Ewing's sarcoma.  
     
     
         73 . The method of  claim 1  wherein the undesired angiogensis occurs in the tumors of neuroblastoma.  
     
     
         74 . The method of  claim 1  wherein the undesired angiogensis occurs in the tumors of osteosarcoma.  
     
     
         75 . The method of  claim 1  wherein the undesired angiogensis occurs in leukemia.  
     
     
         76 . The method of  claim 1  wherein the undesired angiogensis occurs in psoriasis.  
     
     
         77 . The method of  claim 1  wherein the undesired angiogensis occurs in atherosclerosis.  
     
     
         78 . The method of  claim 1  wherein the undesired angiogensis occurs in pemphigoid. Claim  79 . The method of  claim 1  wherein the undesired angiogensis occurs in infections causing retinitis or choroiditis.  
     
     
         80 . The method of  claim 1  wherein the undesired angiogensis occurs in presumed ocular histoplasmosis.  
     
     
         81 . The method of  claim 1  wherein the undesired angiogensis occurs in Best's disease.  
     
     
         82 . The method of  claim 1  wherein the undesired angiogensis occurs in proliferative vitreoretinopathy.  
     
     
         83 . The method of  claim 1  wherein the undesired angiogensis occurs in Bartonellosis.  
     
     
         84 . The method of  claim 1  wherein the undesired angiogensis occurs in acoustic neuroma.  
     
     
         85 . The method of  claim 1  wherein the undesired angiogensis occurs in neurofibroma.  
     
     
         86 . The method of  claim 1  wherein the undesired angiogensis occurs in trachoma.  
     
     
         87 . The method of  claim 1  wherein the undesired angiogensis occurs in pyogenic granulomas.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.